IL-6 Antibody [Biotin]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. Mature rat IL-6 is 187 amino acids (aa) in length that is typically expressed as a 22-28 kDA molecular weight protein. Rat IL-6 shares 39% and 85% aa sequence identity with human and mouse IL-6, respectively. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, function to drive the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise. In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Rat.

We have publications tested in 1 application: ELISA Development.

Showing Publications 1 - 2 of 2.

Publications using BAF506	Applications	Species
Mariano Guardia Clausi, Steven W Levison Delayed ALK5 inhibition improves functional recovery in neonatal brain injury Journal of Cerebral Blood Flow & Metabolism 3/1/2017 [PMID: 26984936]
Roche M, Diamond M, Finn DP In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J. Neuroimmunol., 2006-09-29;181(1):57-67. 2006-09-29 [PMID: 17011047] (ELISA Development, Rat)	ELISA Development	Rat

Array BAF506

• IL-6 Antibodies
• IL-6 Antibody Pair
• IL-6 ELISA Kits
• IL-6 Lysate
• IL-6 Proteins
• IL-6 Proteins and Enzymes
• IL-6 ELISAs